Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

738
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
738
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

788
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
788
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

988
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
988
Cognitivism01:17

Cognitivism

3.2K
Cognitive psychology emerged as a significant field in the mid-20th century. It focused on understanding humans' internal mental processes. This approach emphasizes how people perceive, remember, think, and solve problems—elements critical to human cognition.
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia.

Frontiers in digital health·2026
Same author

Clinicomycological and Dermoscopic Study of 300 Cases of Dermatophytosis in a Tertiary Care Hospital in Dehradun, India.

Indian journal of dermatology·2026
Same author

Patient-reported experiences of cognitive difficulties and their impact on daily life in narcolepsy type 1.

Frontiers in neurology·2026
Same author

Iron Depletion in the Substantia Nigra of Children With Prenatal Alcohol Exposure.

Journal of neurochemistry·2026
Same author

Effect of presence of rigid impurities in a system of annihilating domain walls with dynamic bias.

Physical review. E·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Feb 28, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Cognitive evolution in natalizumab-treated multiple sclerosis patients.

Francois H Jacques1, Brian T Harel2, Adrian J Schembri3

  • 1Clinique Neuro-Outaouais, Canada.

Multiple Sclerosis Journal - Experimental, Translational and Clinical
|June 14, 2017
PubMed
Summary

Natalizumab therapy preserves cognitive function in multiple sclerosis (MS) patients for over two years. This benefit is sustained long-term, regardless of initial patient characteristics or cognitive status.

Keywords:
Cognitionmultiple sclerosisnatalizumabrelapsing–remitting

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K

Related Experiment Videos

Last Updated: Feb 28, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K

Area of Science:

  • Neuroimmunology
  • Cognitive Neurology

Background:

  • Cognitive dysfunction impacts up to 65% of multiple sclerosis (MS) patients.
  • Natalizumab demonstrates efficacy in preserving cognition for the initial two years of treatment.

Purpose of the Study:

  • To evaluate the long-term impact of natalizumab on cognitive function in MS patients beyond two years.
  • To determine if baseline patient characteristics predict cognitive response to natalizumab therapy.

Main Methods:

  • A 24-month observational study involving 63 MS patients treated with natalizumab.
  • Cognitive assessments included the Cogstate battery and Symbol Digit Modalities Test (SDMT).
  • Linear mixed models analyzed cognitive changes over time, considering therapy duration and Multiple Sclerosis Severity Score (MSSS).

Main Results:

  • No patients exhibited sustained cognitive deterioration over the 24-month study period.
  • Baseline cognitive status and other patient characteristics did not influence cognitive trajectory.
  • The Multiple Sclerosis Severity Score (MSSS) was the only significant covariate (p=0.0074).

Conclusions:

  • Natalizumab appears to preserve cognitive function in MS patients with continuous therapy for four to seven years.
  • Cognitive preservation is maintained irrespective of baseline characteristics, including pre-existing cognitive impairment.
  • This suggests natalizumab offers sustained cognitive benefits in managing MS.